Definition
Experimental therapies for metastatic breast cancer can be defined as novel interventions directed toward the more effective treatment of secondary, progressively growing tumors distant from the primary site of the breast. Experimental therapies may include newly developed drug agents or may be different modalities for existing agents, such as the novel indication of a drug in the setting of breast cancer or the combination of approved single agents.
Characteristics
Breast cancer affects one in four women and is the second leading cause of cancer mortality among women in the United States. Globally, breast cancer is the leading cause of cancer mortality in women. Approximately 1 % of all cases of breast cancer occur in men. The majority of mortality associated with the disease is due to the advanced, metastatic form of breast cancer, characterized by progressively growing tumors distant from the...
References
Cardoso F, Castiglione M (2009) Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):15–18
Kataja V, Castiglione M (2009) Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):10–14
Tkaczuk KH (2009) Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin Ther 31(Pt 2):2273–2289
Wong ST (2009) Emerging treatment combinations: integrating therapy into clinical practice. Am J Health Syst Pharm 66:S9–S14
See Also
(2012) Adjuvant. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 75. doi:10.1007/978-3-642-16483-5_107
(2012) Allogeneic. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 138. doi:10.1007/978-3-642-16483-5_194
(2012) EGF. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1211. doi:10.1007/978-3-642-16483-5_1824
(2012) Exemestane. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1357. doi:10.1007/978-3-642-16483-5_6752
(2012) Interleukin. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1892. doi:10.1007/978-3-642-16483-5_3094
(2012) Lapatinib. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1980. doi:10.1007/978-3-642-16483-5_3277
(2012) Monoclonal Antibody. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2367. doi:10.1007/978-3-642-16483-5_6842
(2012) Proliferation. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3004. doi:10.1007/978-3-642-16483-5_4766
(2012) Progesterone Receptor. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2990. doi:10.1007/978-3-642-16483-5_4754
(2012) Sunitinib. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3562. doi:10.1007/978-3-642-16483-5_5575
(2012) Vaccine Therapy. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3879. doi:10.1007/978-3-642-16483-5_6147
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Silveira, A. (2015). Metastatic Breast Cancer Experimental Therapeutics. In: Schwab, M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27841-9_6794-2
Download citation
DOI: https://doi.org/10.1007/978-3-642-27841-9_6794-2
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Online ISBN: 978-3-642-27841-9
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences